AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Roorkee have uncovered a crucial regulatory mechanism in Acinetobacter baumannii -- a highly drug-resistant superbug ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.

The study, published in mBio, the journal of the American Society for Microbiology (ASM), reveals how the pathogen controls its attack and defense systems, paving the way for new treatment strategies.

The road to menopause hasn't always been clearly defined for the stand-up comedian. But now, with open and honest dialogue, she's normalizing a new season of life for herself and others.

I am not a doctor and the following information may not be 100% accurate but, to the best of my ability, the intention of ...

The New Hampshire Department of Health and Human Services (DHHS) said a person from Merrimack County has become the first ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESS Newswire / February 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whole genome sequence- (WGS-) based det ...

The inclusion criteria were: (1) any RCTs that compared daptomycin with other antibiotics in treating SSTIs, (2) included patients were of any age, any gender, had a complicated skin and ...